**Abstract**

**Background:** Suvorexant was launched on November 26, 2014 in Japan. This is marketed as the world's first orexin receptor antagonist to treat insomnia. Orexins is synthesized by neurons in hypothalamus, and promote arousal by acting on the orexin receptors in the arousal center.

Suvorexant promotes sleep by blocking orexin neuropeptides from binding to their receptors. So far, the effects and the side effects have been reported for patients administrated suvorexant alone. There are no reports of effects and side effects of suvorexant combining to other hypnotics. However, suvorexant is often used combining with other sleep promoting medicines such as benzodiazepines and major tranquilizers in psychiatric hospitals. We investigated 116 combined use cases from medical records in Showa University Karasuyama Hospital, Tokyo, Japan, to check an usefulness and a safety about the suvorexant when combining with other sleep promoting medicines. We also investigated the characteristics of patients with insufficient effect of orexin.

**Result:** The diagnoses of patients who received a combination of suvorexant and other sleep promoting medicines in our hospital from December 2014 to September 2015 were schizophrenia (13％), mood disorder (21％)、addiction include alcoholic (8.6％).

62 subjects (54%) continued to take suvorexant over 3 months. 20 subjects(17%) and 23subjects (20%) stop taking orexin due to the side effect and the insufficient effect respectively. 40 subjects (35%) had better effect than other medicines.

**Conclusion**: The result suggested that combined use of suvorexant and other psychotropic medicine were effective and safe for patients with schizophrenia, mood disorder and alcoholic who took benzodiazepines or major tranquilizers.

On the other hand, the suvorexant was ineffective for a part of patients. A further investigation will be needed for the ineffective cases.

The first limitation of this study was that this study investigated the effect and the side effect of suvorexant only by medical records so that we did not notice symptoms without description on the records. The second limitation was that we could not concern about placebo effect
